Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Phase II results with a new form of tPA, TNK-tPA, show that the agent given as a single intravenous injection
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury